Aptose Biosciences Inc. (NASDAQ:APTO) (TSE:APS) CEO William G. Rice purchased 10,000 shares of the company’s stock in a transaction on Thursday, April 18th. The stock was purchased at an average cost of $1.85 per share, for a total transaction of $18,500.00. Following the purchase, the chief executive officer now directly owns 153,014 shares in the company, valued at $283,075.90. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website.
NASDAQ:APTO opened at $1.83 on Monday. The stock has a market capitalization of $73.66 million, a P/E ratio of -2.13 and a beta of 1.61. Aptose Biosciences Inc. has a 52-week low of $1.57 and a 52-week high of $4.55.
Aptose Biosciences (NASDAQ:APTO) (TSE:APS) last released its earnings results on Tuesday, March 12th. The biotechnology company reported ($0.17) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.16) by ($0.01). Research analysts expect that Aptose Biosciences Inc. will post -0.72 EPS for the current year.
Several large investors have recently added to or reduced their stakes in the stock. Virtu Financial LLC acquired a new stake in shares of Aptose Biosciences in the first quarter valued at about $198,000. Geode Capital Management LLC acquired a new stake in shares of Aptose Biosciences in the fourth quarter valued at about $33,000. Noven Financial Group Inc. acquired a new stake in shares of Aptose Biosciences in the fourth quarter valued at about $27,000. Patriot Financial Group Insurance Agency LLC increased its position in shares of Aptose Biosciences by 11.4% in the fourth quarter. Patriot Financial Group Insurance Agency LLC now owns 57,429 shares of the biotechnology company’s stock valued at $110,000 after acquiring an additional 5,890 shares during the last quarter. Finally, Renaissance Technologies LLC increased its position in shares of Aptose Biosciences by 1,130.9% in the third quarter. Renaissance Technologies LLC now owns 183,401 shares of the biotechnology company’s stock valued at $477,000 after acquiring an additional 168,501 shares during the last quarter. 7.68% of the stock is currently owned by institutional investors and hedge funds.
About Aptose Biosciences
Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies.
Further Reading: How to invest in a bear market
Receive News & Ratings for Aptose Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptose Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.